Dr. Salehizadeh has over 20 years of healthcare operating and investment experience. At NaviMed, he sits on the firm’s Investment Committee and is responsible for leading investments and overseeing portfolio companies with a particular focus on healthcare providers and pharmaceutical services. Prior to co-founding NaviMed Capital, he was a General Partner at Highland Capital Partners, where he focused on growth stage healthcare investments.
Prior to joining Highland Capital Partners in 2004, Dr. Salehizadeh spent several years in a variety of healthcare operational roles at publicly traded and emerging growth companies.
Dr. Salehizadeh led NaviMed’s investment in and currently serves on the Board of Directors of Advantage Surgical & Wound Care and CiTRUS Health Group. He also serves on the Board of Directors of OPN Healthcare, and Aledade. Dr. Salehizadeh previously led NaviMed’s investments in CenterPointe Behavioral Health System (sold to Acadia Healthcare), The CM Group (sold to OPEN Health/Astorg), Lighthouse Lab Services (majority recapitalized), and Velocity Clinical Research (sold to GHO).
He also has served on the Board of Directors of several companies including Auris Health (sold to Johnson & Johnson for up to $5.7 billion), BARRX Medical (sold to Covidien for $400 million), Hyperion Therapeutics (IPO; sold to Horizon plc for $1.1 billion), Lumere (sold to GHX), and Opgen (IPO). In addition, he sourced or was actively involved in Highland Capital Partners’ investments in AVEO (IPO), Baronova, Conor Medsystems (IPO; sold to Johnson & Johnson for $1.4 billion), kyruus, and Pharmaca Integrative Pharmacy.
Dr. Salehizadeh holds an AB in Molecular Biology from Princeton University, an MD and Master’s in Science in Health Policy from Columbia University, and an MBA from Harvard Business School. He is also a graduate of the Kauffman Fellows Program.Email Bijan Salehizadeh